Diclofenac Duo® 75mg 2 forms of diclofenac in 1 intelligent capsule 1. NAME OF THE MEDICINAL PRODUCT Trade name: Diclofenac Duo INN: Diclofenac sodium 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release capsule, hard, contains 75 mg diclofenac sodium.(25 mg diclofenac sodium in gastroresistant form, 50 mg diclofenac sodium in prolonged-release form). 3.
Prof-harenberg.deName der Studie
Titel der abgelaufenden klinischen Studien
Stand der Studie
A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely III Medical Subjects During and Following Hospitalization A Safety and Efficacy Trial Evaluating the Use of Apixaban for the extended Treatment of Deep Vein Thrombosis and A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial An open-label comparison of the efficacy and safety of the low-molecular-weight heparin Certoparin (3000 U anti-Xa once daily with unfractionated heparin for the prevention of thromboembolic complications in acutely ill non-surgical patients A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin (3000 U anti-Xa o.d.) with unfractionated heparin (5000 IU t.i.d) in the prophylaxis of thromboembolic events in acutely ill medical patients Cost effectiveness of Computer Assisted Dosage (QLG4 CT 2002-02175, European Project) EINSTEIN VTE Extension Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism Placebokontrollierte, parallele multizentrische Doppelblindstudie zur Langzeitprophylaxe gegen venöse Thromboembolien bei akut erkrankten, länger Zeit immobilisierten Patienten An international, multicenter, observational study to gather and analyze data on ACS (Acute Coronary Syndrome) patients A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate A randomized, double-blind, placebo-controlled study of the safety and tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of XXX in Subjects with Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability with Warfarin Untersuchung zum Einfluss des Cytochrom P450 2C9-Genotyps auf den Dosisbedarf und die Plasmakonzentration von Randomized Evaluation of Long term anticoagulant therapy (RELY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial Long Term Open Label Follow-Up Treatment of Patients with Non-Valvular Atrial Fibrillation who have been previously treated with Dabigatran for the prevention of stroke and systemic embolism in the RE-LY Trial: a non comparative, multi centre trial Risikofaktoren, Behandlung und Folgen für Notaufnahmepatienten mit Vorhofflimmern in verschiedenen Regionen der Welt A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venousthromboembolism.
A multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy
SIGNS OF MENTAL HEALTH CONDITIONS……….…….2 X FACT FOCUS : RESPONDING TO SIGNS OF MENTAL HEALTH CONDITIONS A PUBLICATION OF THE CALIFORNIA DEPARTMENT OF DEVELOPMENTAL PROMOTING CHOICE AND OPTIONS IN THE COMMUNITY FOR INDIVIDUALS WITH DEVELOPMENTAL DISABILITES Understanding Mental Health Conditions What can you do? mental illnesses, can affect anyone, includin